دورية أكاديمية
أعرض في EDS

The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice.

التفاصيل البيبلوغرافية
العنوان: The malignant transformation potential of the oncogene STYK1/NOK at early lymphocyte development in transgenic mice.
المؤلفون: Yang Y; Department of Pathogen Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China., Liu L; Department of Pathogen Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & School of Basic Medicine, Peking Union Medical College, Beijing, 100005, China., Tucker HO; Molecular Biosciences, Institute for Cellular and Molecular Biology, University of Texas at Austin, 1 University Station A5000, Austin, TX, 78712, USA.
المصدر: Biochemistry and biophysics reports [Biochem Biophys Rep] 2024 Apr 12; Vol. 38, pp. 101709. Date of Electronic Publication: 2024 Apr 12 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101660999 Publication Model: eCollection Cited Medium: Internet ISSN: 2405-5808 (Electronic) Linking ISSN: 24055808 NLM ISO Abbreviation: Biochem Biophys Rep Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2015]-
مستخلص: B-cell Chronic Lymphocytic Leukemia (B-CLL) is a malignancy caused by the clonal expansion of mature B lymphocytes bearing a CD5 + CD19 + (B1) phenotype. However, the origin of B-CLL remains controversial. We showed previously that STYK1/NOK transgenic mice develop a CLL-like disease. Using this model system in this study, we attempt to define the stage of CLL initiation. Here, we show that the phenotype of STYK1/NOK-induced B-CLL is heterogeneous. The expanded B1 lymphocyte pool was detected within peripheral lymphoid organs and was frequently associated with the expansions of memory B cells. Despite this immunophenotypic heterogeneity, suppression of B cell development at an early stage consistently occurred within the bone marrow (BM) of STYK1/NOK-tg mice. Overall, we suggest that enforced expression of STYK1/NOK in transgenic mice might significantly predispose BM hematopoietic stem cells (HSCs) towards the development of B-CLL.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Authors.)
References: N Engl J Med. 1995 Oct 19;333(16):1052-7. (PMID: 7675049)
Cancer Res. 2005 Dec 1;65(23):10838-46. (PMID: 16322230)
Biochem Biophys Res Commun. 2022 Oct 20;626:51-57. (PMID: 35970044)
Genes Chromosomes Cancer. 1993 Sep;8(1):49-59. (PMID: 7691159)
Blood. 2003 Oct 15;102(8):2994-3002. (PMID: 12829608)
Blood. 2003 Jun 15;101(12):4944-51. (PMID: 12595313)
J Immunol. 2002 Jan 1;168(1):118-26. (PMID: 11751954)
Lancet. 2008 Mar 22;371(9617):1017-29. (PMID: 18358929)
Stem Cell Res. 2017 Aug;23:109-118. (PMID: 28732240)
Blood. 2004 May 1;103(9):3490-5. (PMID: 14695232)
Blood. 2002 Dec 15;100(13):4609-14. (PMID: 12393534)
J Exp Med. 1994 Jul 1;180(1):329-39. (PMID: 8006591)
Blood. 2005 Mar 1;105(5):2036-41. (PMID: 15514014)
Hematology Am Soc Hematol Educ Program. 2006;:273-8, 512. (PMID: 17124072)
Leukemia. 2010 Jan;24(1):133-40. (PMID: 19946263)
J Exp Med. 1993 Sep 1;178(3):951-60. (PMID: 8350062)
J Exp Med. 1997 Aug 29;186(5):705-17. (PMID: 9271586)
Stem Cells. 2007 Jun;25(6):1339-47. (PMID: 17379763)
Nature. 2012 Sep 13;489(7415):309-12. (PMID: 22885698)
J Exp Med. 1998 Nov 2;188(9):1679-89. (PMID: 9802980)
N Engl J Med. 2005 Feb 24;352(8):804-15. (PMID: 15728813)
Blood. 2011 Jan 13;117(2):563-74. (PMID: 20940416)
Immunity. 2002 Sep;17(3):277-88. (PMID: 12354381)
J Immunol. 1989 Nov 15;143(10):3303-8. (PMID: 2809203)
Blood. 2002 Jun 1;99(11):4087-93. (PMID: 12010811)
Blood. 1999 Sep 15;94(6):1840-7. (PMID: 10477712)
J Immunol. 2016 Sep 15;197(6):2522-31. (PMID: 27534555)
Blood Adv. 2017 Nov 28;1(25):2444-2455. (PMID: 29296894)
Blood. 2009 Jul 2;114(1):33-7. (PMID: 19420353)
Nat Rev Dis Primers. 2017 Jan 19;3:16096. (PMID: 28102226)
Immunol Today. 1994 Jun;15(6):288-94. (PMID: 7520700)
Cancer Cell. 2011 Aug 16;20(2):246-59. (PMID: 21840488)
J Biol Chem. 2004 Sep 10;279(37):38701-9. (PMID: 15226319)
Blood. 2004 Jun 15;103(12):4389-95. (PMID: 14962897)
Cell Stem Cell. 2010 Jul 2;7(1):2-4. (PMID: 20621039)
J Mol Biol. 2003 Dec 5;334(4):733-49. (PMID: 14636599)
Immunol Today. 2000 May;21(5):204-6. (PMID: 10782048)
Eur J Immunol. 1998 Nov;28(11):3850-6. (PMID: 9842928)
Crit Rev Oncol Hematol. 2007 Dec;64(3):234-46. (PMID: 17544290)
Exp Hematol. 2003 Dec;31(12):1284-91. (PMID: 14662336)
Cytometry B Clin Cytom. 2008 May;74(3):139-49. (PMID: 18061951)
Blood. 2002 Aug 15;100(4):1410-6. (PMID: 12149225)
Blood. 2011 Feb 10;117(6):1781-91. (PMID: 21148333)
Trends Mol Med. 2007 Nov;13(11):470-81. (PMID: 17981087)
Cancer Res. 2004 May 15;64(10):3491-9. (PMID: 15150103)
J Immunol. 1995 May 1;154(9):4233-9. (PMID: 7722283)
Leuk Lymphoma. 2001 Jul;42(3):499-506. (PMID: 11699415)
J Exp Med. 1992 Oct 1;176(4):1073-81. (PMID: 1402653)
J Exp Med. 1991 May 1;173(5):1213-25. (PMID: 1827140)
J Autoimmun. 2015 Jan;56:81-6. (PMID: 25468260)
Nat Rev Cancer. 2016 Mar;16(3):145-62. (PMID: 26911189)
Proc Natl Acad Sci U S A. 1995 Jan 17;92(2):626-30. (PMID: 7831340)
Leukemia. 2017 Jun;31(6):1340-1347. (PMID: 28074063)
Pol Arch Med Wewn. 1999 Sep;102(3):753-62. (PMID: 10949882)
Blood. 2003 Feb 1;101(3):1087-93. (PMID: 12393552)
Blood. 1999 Sep 15;94(6):1848-54. (PMID: 10477713)
Haematologica. 2008 Mar;93(3):413-22. (PMID: 18287138)
J Exp Med. 1993 Apr 1;177(4):1039-46. (PMID: 7681468)
فهرسة مساهمة: Keywords: B lymphocyte; B1 cells; CLL; HSC; Lymphadenectasis; STYK1/NOK
تواريخ الأحداث: Date Created: 20240419 Latest Revision: 20240425
رمز التحديث: 20240425
مُعرف محوري في PubMed: PMC11024497
DOI: 10.1016/j.bbrep.2024.101709
PMID: 38638675
قاعدة البيانات: MEDLINE
الوصف
تدمد:2405-5808
DOI:10.1016/j.bbrep.2024.101709